Welfare
We have three very different areas of work:
B2B: We work with hospitals, laboratories and private clinics offering next generation sequencing (NGS) services – exome (WES), genome (WGS) and customizable virtual gene panels -, genetic counseling consultation services prior and subsequent to the performance of a diagnostic genetic test and bioinformatics analysis services for clinical diagnosis. We also offer biomarker analysis services with great relevance in genomic medicine, especially in the area of pharmacogenetics. These analyses include clinical recommendations for more than 50 drugs.
2. B2C: We perform genotyping studies using microarray technology through a saliva sample that allow us to obtain information and genetic associations covering areas as diverse as genetic origins (ancestry), nutrigenomics, sports, genetic behavior, predisposition to diseases through the analysis of biomarkers of the GSA array, pharmacogenetics (GSA array) and innovative, curious and fun studies such as your predisposition to mosquito bites or various sleep traits – insomnia, snoring, etc..
3. R&D: currently focused on the optimization of a new polygenic algorithm or Polygenic Risk Score (PRS) for the estimation of risk/susceptibility to various diseases supported and validated with genomic data and clinical information provided by UKBiobank samples (https://www.ukbiobank.ac.uk/) as validation of the analysis of more than 20k microarrays already performed by us.
SERVICES
PRODUCTS
DNA kit through a saliva sample that allows you to obtain a detailed report with information on genetic association in areas as diverse as genetic origins (ancestry), nutrigenomics, sports, genetic behavior, predisposition to diseases, pharmacogenetics and innovative, curious and fun studies such as your predisposition to mosquito bites or various sleep traits – insomnia, snoring…
In the B2B world we have active collaborations for genetic analysis for diagnostics in pediatric oncology mainly, and several research projects in the approval process:
TAiGen: Project submitted to the Challenges Collaboration program in consortium with the Recoletas Group Hospitals group and the International Research Institute for Artificial Intelligence and Computer Science Foundation (AIR Institute). The project focuses on the study of genotype-phenotype correlation and prevention of sarcopenia assessed through medical imaging and genetic studies in patients with head and neck cancer treated with radiotherapy/chemotherapy.
Meet&Match: Project pending resolution for one of the programs organized by EIT Health – Disruptive solutions for early disease identification and interdisciplinary treatment of eosinophilic diseases.
3. Horizon 20-30 (Horizon Europe Framework Programme): Project to determine risk susceptibility to cardiovascular diseases in the field of cardiogenomics. Development of a polygenic risk prediction algorithm for heart diseases such as acute myocardial infarction.
4. Call for grants to carry out R&D activities programs between research groups of the Community of Madrid in Biomedicine (2022) – P2022/BMD-7426. Partner in the project: “Integration of global genomic methylome methylome methylation profiles in children with suspected rare diseases as a diagnostic complement: unraveling variants of uncertain significance”.
5. Development of a new PRS (Polygenic Risk Score) using genomic and clinical data from the UK Biobank database as a benchmark.
6. Detection of monogenic disease carriers in the clinical setting for pre-reproductive genetic counseling.
In the B2C area we are promoting several research projects such as:
1. Development of a scoring system that represents the compatibility of couples focusing on their offspring, such as the possible development of recessive monogenic diseases.
2. Development of a bioinformatics algorithm for optimization of fine subpopulation detection for the identification of a person’s ancestry.
B2B: Our offer is addressed to public and private clinics, laboratories and clinical centers where we provide solutions in the WGS/WES sequencing part of the value chain, as well as bioinformatics analysis for both (1) genetic diagnostics and (2) genomic risk identification of diseases based on PRS (Polygenic Risk Score) algorithms.
B2C: Our offer is addressed to the end customer, with genotyping solutions and access to the DNATRO report through our platform (dynamic and updated), also compatible with the upload of RAW DNA data from established players in the industry such as 23&Me, MyHeritage, Ancestry DNA… (26M customers already genotyped + penetration of new customers).
ADNTRO Genetics
Address: Colonia de Sant Pere, Finca Es pinaret. 07579 Artà, Palma de Mallorca
E-mail: mendel@adntro.com
Phone: +34 676 913 386
